Intratumoral therapies and in-situ vaccination for melanoma
Skin cancers are among the most physically accessible malignancies, so local delivery of a medication into the tumor, so-called intratumoral therapy, is an appealing route of drug administration. Intratumoral therapies have the potential to increase local drug concentration and/or attract immune cel...
Main Authors: | Laura A. Huppert, Adil I. Daud |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2022-05-01
|
Series: | Human Vaccines & Immunotherapeutics |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/21645515.2021.1890512 |
Similar Items
-
Insights into the Molecular Mechanisms Behind Intralesional Immunotherapies for Advanced Melanoma
by: Dejan Vidovic, et al.
Published: (2020-05-01) -
Abscopal responses in patients with metastatic melanoma involving skin and subcutaneous tissues treated with intralesional IL2 plus BCG
by: Dejan Vidovic, et al.
Published: (2023-04-01) -
Intratumoral bacteria in uveal melanoma: A case report
by: Katherine Vega Escobar, et al.
Published: (2023-06-01) -
Topical and Intralesional Immunotherapy for Melanoma In Situ: A Review
by: Sandra Martínez-Fernández, et al.
Published: (2023-09-01) -
Advances in Intralesional Therapy for Locoregionally Advanced and Metastatic Melanoma: Five Years of Progress
by: Danielle K. DePalo, et al.
Published: (2023-02-01)